Valsartan in Acute Myocardial Infarction
Initiatives
-
In a double-blind trial, we compared the effect of the angiotensin-receptor blocker valsartan, the ACE inhibitor captopril, and the combination of the two on mortality in this population of patients.
*Note: All published information has been collected from the article referenced in the Marker Paper box below. Therefore, there may be variations with more advanced versions of the study.*
| Investigators | Contacts |
|---|---|
|
Design
- Study design
- Clinical trial cohort
- Follow Up
- A median follow-up of 24.7 months,
Marker Paper
Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003 Nov 13;349(20):1893-906. doi: 10.1056/NEJMoa032292. Epub 2003 Nov 10. Erratum in: N Engl J Med. 2004 Jan 8;350(2):203.
PUBMED 14610160
Recruitment
- Sources of Recruitment
-
- Individuals
Number of participants
- Number of participants
- 14,703
- Number of participants with biosamples
- Supplementary Information
- Patients with myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both.
Access
Availability of data and biosamples
| Data | |
| Biosamples | |
| Other |